ORGO trades 95.3% below Wall Street's consensus target of $2.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ORGO achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 10, 2026, Organogenesis Holdings Inc. (ORGO) has a Wall Street consensus price target of $2.50, based on estimates from 6 covering analysts. With the stock currently trading at $1.29, this represents a potential upside of +95.3%. The company has a market capitalization of $166M.
Analyst price targets range from a low of $2.00 to a high of $3.00, representing a 40% spread in expectations. The median target of $2.50 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, ORGO trades at a trailing P/E of 8.6x. Analysts expect EPS to grow -96.4% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $0.24, with bear and bull scenarios of $0.15 and $0.31 respectively. Model confidence stands at 41/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 MDXGMiMedx Group, Inc. | $681M | $4.67 | $7.67 | +66.0% | Buy | — | 15 |
 NVCRNovocure Ltd | $1.7B | $14.58 | $26.00 | +82.8% | Buy | — | 15 |
 TELATELA Bio, Inc. | $50M | $1.11 | — | — | — | — | — |
 APOGApogee Enterprises, Inc. | $847M | $40.59 | $61.33 | +50.4% | Hold | 11.9x | 6 |
 IONSIonis Pharmaceuticals, Inc. | $7.5B | $45.28 | $84.08 | +94.2% | Buy | — | 33 |
 MGRXMangoceuticals, Inc. | $7M | $0.42 | — | — | — | — | — |
 SKINSkinHealth Systems Inc. | $71M | $0.55 | $1.50 | +163.7% | Hold | — | 14 |
 XTNTXtant Medical Holdings, Inc. | $46M | $0.33 | — | — | — | — | — |
 ANIKAnika Therapeutics, Inc. | $262M | $19.58 | $21.00 | +9.2% | Buy | 18.3x | 7 |
 NAUTNautilus Biotechnolgy, Inc. | $286M | $2.25 | $3.50 | +92.3% | Buy | — | 5 |
Quick answers to the most common questions about buying ORGO stock.
The consensus Wall Street price target for ORGO is $2.5, representing 95.3% upside from the current price of $1.29. With 6 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
ORGO has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $2.5 implies 95.3% upside from current levels.
ORGO's current price is $1.29 with a consensus target of $2.5 (95.3% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $3 for ORGO, while the most conservative target is $2. The consensus of $2.5 represents the median expectation. Our quantitative valuation model projects a bull case target of $0 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
ORGO is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ORGO stock forecast based on 6 Wall Street analysts shows a consensus price target of $2.5, with estimates ranging from $2 (bear case) to $3 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $0, with bear/bull scenarios of $0/$0.
Our quantitative valuation model calculates ORGO's fair value at $0 (base case), with a bear case of $0 and bull case of $0. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 41/100.
Wall Street analysts are very optimistic on ORGO, with a "Buy" consensus rating and $2.5 price target (95.3% upside). 4 of 6 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ORGO analyst price targets range from $2 to $3, a 40% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $2.5 consensus represents the middle ground. Our model's $0-$0 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.